Jump to content

MRNA-1283: Difference between revisions

From Wikipedia, the free encyclopedia
Content deleted Content added
+ cite
Misc citation tidying. | Use this bot. Report bugs. | #UCB_CommandLine 1198/1853
Line 1: Line 1:
{{cs1 config|name-list-style=vanc}}
{{Lowercase title}}
{{Lowercase title}}
{{short description|Vaccine candidate against COVID-19}}
{{short description|Vaccine candidate against COVID-19}}
Line 43: Line 44:
}}
}}
{{COVID-19 pandemic sidebar}}
{{COVID-19 pandemic sidebar}}
'''mRNA-1283''' is a [[COVID-19 vaccine]] candidate developed by [[Moderna]].<ref>{{#invoke:Cite web| |title=A Study to Evaluate Safety, Reactogenicity, and Immunogenicity of mRNA-1283 and mRNA-1273 Vaccines in Healthy Adults Between 18 Years and 55 Years of Age to Prevent COVID-19 |url=https://clinicaltrials.gov/ct2/show/NCT04813796 |website=[[ClinicalTrials.gov]] |date=24 March 2021 |id=NCT04813796 |access-date=17 August 2021 }}</ref><ref>{{#invoke:Cite web| |title=A Study to Evaluate the Immunogenicity and Safety of mRNA-1283 COVID-19 Vaccine Boosters |url=https://clinicaltrials.gov/ct2/show/NCT05137236 |website=[[ClinicalTrials.gov]] |date=30 November 2021 |id=NCT05137236 |access-date=30 November 2021 }}</ref>
'''mRNA-1283''' is a [[COVID-19 vaccine]] candidate developed by [[Moderna]].<ref>{{#invoke:Cite web||title=A Study to Evaluate Safety, Reactogenicity, and Immunogenicity of mRNA-1283 and mRNA-1273 Vaccines in Healthy Adults Between 18 Years and 55 Years of Age to Prevent COVID-19 |url=https://clinicaltrials.gov/ct2/show/NCT04813796 |website=[[ClinicalTrials.gov]] |date=24 March 2021 |id=NCT04813796 |access-date=17 August 2021 }}</ref><ref>{{#invoke:Cite web||title=A Study to Evaluate the Immunogenicity and Safety of mRNA-1283 COVID-19 Vaccine Boosters |url=https://clinicaltrials.gov/ct2/show/NCT05137236 |website=[[ClinicalTrials.gov]] |date=30 November 2021 |id=NCT05137236 |access-date=30 November 2021 }}</ref>


An expectation, or hope seems to be that this "next generation" vaccine can be stored at regular refrigerator temperature (2-5 °C). <ref name=":0">{{Cite web |title=CTG Labs - NCBI |url=https://clinicaltrials.gov/study/NCT05815498 |access-date=2023-08-01 |website=clinicaltrials.gov}}</ref>
An expectation, or hope seems to be that this "next generation" vaccine can be stored at regular refrigerator temperature (2-5 °C). <ref name=":0">{{Cite web |title=CTG Labs - NCBI |url=https://clinicaltrials.gov/study/NCT05815498 |access-date=2023-08-01 |website=clinicaltrials.gov}}</ref>

Revision as of 09:58, 30 December 2023

mRNA-1283
Vaccine description
TargetSARS-CoV-2
Vaccine typemRNA
Clinical data
Trade namesSpikevax[1]
Routes of
administration
Intramuscular

mRNA-1283 is a COVID-19 vaccine candidate developed by Moderna.[2][3]

An expectation, or hope seems to be that this "next generation" vaccine can be stored at regular refrigerator temperature (2-5 °C). [4]

Clinical Trial

In December, Moderna started a clinical trial which would evaluate the vaccine's ability to provoke an immune response and its safety.[5] As of September 2022, the trial is in Phase 2 [6]

An expectation, or hope seems to be that this "next generation" vaccine can be stored at regular refrigerator temperature. [4]

References

  1. ^ "Moderna Announces Significant Advances Across Industry-Leading mRNA Portfolio at 2021 R&D Day". Bloomberg. 9 September 2021. Retrieved 29 April 2022.
  2. ^ "A Study to Evaluate Safety, Reactogenicity, and Immunogenicity of mRNA-1283 and mRNA-1273 Vaccines in Healthy Adults Between 18 Years and 55 Years of Age to Prevent COVID-19". ClinicalTrials.gov. 24 March 2021. NCT04813796. Retrieved 17 August 2021.
  3. ^ "A Study to Evaluate the Immunogenicity and Safety of mRNA-1283 COVID-19 Vaccine Boosters". ClinicalTrials.gov. 30 November 2021. NCT05137236. Retrieved 30 November 2021.
  4. ^ a b "CTG Labs - NCBI". clinicaltrials.gov. Retrieved 1 August 2023.
  5. ^ Yassini P, Hutchens M, Paila YD, Schoch L, Aunins A, Siangphoe U, Paris R (December 2023). "Interim analysis of a phase 1 randomized clinical trial on the safety and immunogenicity of the mRNA-1283 SARS-CoV-2 vaccine in adults". Human Vaccines & Immunotherapeutics. 19 (1): 2190690. doi:10.1080/21645515.2023.2190690. PMC 10128428. PMID 37074202.
  6. ^ "A Study to Evaluate the Immunogenicity and Safety of mRNA-1283 COVID-19 Vaccine Boosters". ClinicalTrials.org. Retrieved 29 April 2022.